Connect your AI

Inhibrx Biosciences, Inc. INBX PP&E (Net)

PP&E (Net) at other companies

PfizerPFE

$19.4B+5.8%

Rogers CorporationROG

$363.9M-3.1%

Merck & Co.MRK

$25.43B+2.6%

Gilead SciencesGILD

$5.64B+4.0%

Nuvation BioNUVB

$535K-4.8%

ImmunomeIMNM

$17.08M+55.9%

Other financials

Income statement

Revenue--100%

Operating income-$30.9M+27.9%

Net income-$33.4M+22.8%

EPS (diluted)-$2.15+23.2%

Balance sheet

Cash & equivalents$161.7M-25.3%

Total debt$180.9M+69.8%

Total equity-$21.0M-122%

Total assets$184.0M-24.2%

Cash flow

Operating cash flow-$38.0M-5.9%

CapEx--100%

Free cash flow-$38.0M-5.9%

Valuation

Market cap$1.4B+546%

Enterprise value$1.42B+1,233%

P/S1,073.7×-280×

Profitability

Operating margin-10,386.5%-5,025pp

Net margin-10,773.5%-878,492pp

FCF margin-9,986.5%-4,727pp

Returns & leverage

Return on equity-197.8%-2,158pp

Debt / equity13.4×+13.3×

Current ratio6.5×+1.3×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inhibrx Biosciences, Inc.'s pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Inhibrx Biosciences, Inc.'s PP&E (net)?: Inhibrx Biosciences, Inc. (INBX) reported PP&E (net) of $3.2M in Q1 2026.
How has Inhibrx Biosciences, Inc.'s PP&E (net) changed year-over-year?: Inhibrx Biosciences, Inc.'s PP&E (net) decreased by 42.4% year-over-year, from $5.55M to $3.2M.
What is the long-term trend for Inhibrx Biosciences, Inc.'s PP&E (net)?: Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s PP&E (net) has grown at a -23.7% compound annual growth rate (CAGR), from $6.42M to $3.73M.
What does PP&E (net) mean?: Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.